Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - Summary - MDSpire
From the Journals

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

Share

The phase III KEYNOTE-905/EV-303 trial by Vulsteke et al demonstrated that perioperative enfortumab vedotin and pembrolizumab significantly improved event-free and overall survival in patients with muscle-invasive bladder cancer who were ineligible for cisplatin-based chemotherapy. Conducted with 344 patients, this open-label trial showed that 74.7% of those receiving the therapy achieved event-free survival at two years compared to 39.4% in the control group. The study also highlighted the safety profile of the regimen, with notable adverse events recorded.

Original Source(s)

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

  • by Matthew Stenger

  • April 7, 2026

Related Content

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...